Company Overview - BIO-RAY BIOTECH. CO., LTD. PABP BRANCH
1YRSBIO-RAY BIOTECH. CO., LTD. PABP BRANCH

Обзор компании

Альбом компании

Основная информация
With over 35 years of experience in medical research and clinical work, our expertise lies in immunology and oncology. We adhere to the belief of seeking non-harmful remedies and strive to develop natural, safe, and effective healthcare methods. Our outstanding research achievements include inventing DNA vaccines for treating allergic diseases as early as 1996, publishing in the prestigious scientific journal "Nature Medicine," and establishing our reputation as an internationally renowned immunology expert. Throughout years of clinical work, we observed that current treatments for immune-related diseases mostly focus on symptom control without addressing the underlying immune system disorder. These treatments are like "band-aid solutions" that merely provide temporary relief. After dedicated research efforts, we successfully developed the first indigenous anti-allergic probiotic strain in Taiwan. Through rigorous scientific evidence from cell experiments, animal studies, and human trials, our product obtained international patents and certifications as a nationally recognized health food that assists in allergy management. Its success in the market ignited the probiotics trend in Taiwan, and even after more than a decade, its popularity remains strong, propelling the functional probiotics industry in Taiwan forward.
  • Транзакции
    -
  • Время отклика
    ≤12h
  • Частота откликов
    100%
Тип компании
Производитель
Страна / Регион
Taiwan, China
Основные продуктыВсего сотрудников
-
Год основания
2012
Сертификаты(3)
Сертификаты на продукцию
-
Патенты
-
Товарные знаки
-
Основные рынки

Емкость продукта

Информация о заводе

Размер завода
3,000-5,000 square meters
Местоположение завода
No. 21-3, Shennong E. Rd., Changzhi Township, Pingtung County 90846, Taiwan (R.O.C.)
Число производственных линий
3
Контрактное производство
OEM Service Offered
Годовой выпуск
Above US$100 Million